Context Therapeutics (CNTX) Earnings Date, Estimates & Call Transcripts $2.23 +0.05 (+2.29%) (As of 12:00 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateNov. 14EstimatedActual EPS (Aug. 7) -$0.04 Beat By $0.04 Consensus EPS (Aug. 7) -$0.08 Get Context Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CNTX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCNTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CNTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Timothy SykesCountdown to the biggest trade of my 25 yr careerTim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Context Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.23)($0.23)($0.23)Q2 20241($0.27)($0.27)($0.27)Q3 20242($0.28)($0.16)($0.22)Q4 20242($0.31)($0.10)($0.21)FY 20246($1.09)($0.76)($0.93)CNTX Earnings Date and InformationContext Therapeutics last posted its earnings results on August 7th, 2024. The reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.04. Context Therapeutics has generated ($1.06) earnings per share over the last year (($1.06) diluted earnings per share). Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.32) per share. Context Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off prior year's report dates.Read More Context Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/7/2024-($0.08)($0.04)+$0.04($0.04)--5/8/2024Q1 2024($0.38)($0.23)+$0.15($0.23)-- 3/21/2024Q4 2023($0.35)($0.42)($0.07)($0.42)-- 11/9/2023Q3 2023($0.30)($0.37)($0.07)($0.37)-- 8/9/2023Q2 2023($0.20)($0.31)($0.11)($0.31)-- 5/10/2023Q1 2023($0.19)($0.40)($0.21)($0.40)-- Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/22/2023Q4 2022($0.30)($0.22)+$0.08($0.22)-- 11/9/2022Q3 2022($0.25)($0.24)+$0.01($0.24)-- 8/11/2022Q2 2022($0.25)($0.25)-($0.25)-- 5/11/2022Q1 2022($0.24)($0.22)+$0.02($0.22)-- 12/2/2021Q3 2021-($4.00)($4.00)($4.00)-- Context Therapeutics Earnings - Frequently Asked Questions When is Context Therapeutics's earnings date? Context Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on CNTX's earnings history. Did Context Therapeutics beat their earnings estimates last quarter? In the previous quarter, Context Therapeutics (NASDAQ:CNTX) reported ($0.04) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.08) by $0.04. Learn more on analysts' earnings estimate vs. CNTX's actual earnings. How much profit does Context Therapeutics generate each year? Context Therapeutics (NASDAQ:CNTX) has a recorded net income of -$23.96 million. CNTX has generated -$1.06 earnings per share over the last four quarters. What is Context Therapeutics's EPS forecast for next year? Context Therapeutics's earnings are expected to grow from ($0.40) per share to ($0.32) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies UNCY Earnings Results ATXS Earnings Results YMAB Earnings Results STOK Earnings Results TRDA Earnings Results TNGX Earnings Results SLRN Earnings Results HUMA Earnings Results EXAI Earnings Results ORIC Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer Spending This page (NASDAQ:CNTX) was last updated on 11/1/2024 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredCapitalize on Generational Opportunities in the ‘Roaring 2020s’The industrial revolutions in our country's past have connected the world in ways never thought possible… C...Unstoppable Prosperity | SponsoredIf You’re Even Thinking of Investing in AI, Read This First.If you're starting to invest in AI or even just thinking about it, it can feel overwhelming and even a bit sca...Brownstone Research | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored4 Trades for $4?! (Next Pick Goes LIVE Tues!)Bryan wants show you his unique trading philosophy... It allows his members to take profits early again and...Monument Traders Alliance | SponsoredIs your portfolio prepared for AI 2.0?AI has exploded ever since ChatGPT set the world on fire near the end of 2022. Numerous companies with conn...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
